DANIEL BREEYEAR: Open Payments
NPI 1922620178 · NISKAYUNA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$96,369 in 270 payments from 16 companies in 2025. Trend: 2023 $23,458 · 2024 $25,404 · 2025 $96,369
Speaker / faculty: $38,760Honoraria: $29,990Travel & lodging: $17,783Food & beverage: $6,648Consulting: $3,188
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 105 | $55,514 |
| Axsome Therapeutics, Inc. | 87 | $38,725 |
| Alkermes, Inc. | 10 | $529 |
| Janssen Pharmaceuticals, Inc | 8 | $317 |
| Otsuka America Pharmaceutical, Inc. | 13 | $296 |
| Neurocrine BioSciences, Inc. | 17 | $276 |
| ABBVIE INC. | 6 | $227 |
| Lundbeck LLC | 6 | $124 |
| Teva Pharmaceuticals USA, Inc. | 3 | $87 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
Products named: CAPLYTA, Auvelity, ARISTADA, REXULTI, INGREZZA, SPRAVATO, VRAYLAR, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
